Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

Inclusion Criteria:

- Diagnosis of gMG [Myasthenia Gravis Foundation of America (MGFA) Class II-IVa] at
Screening

- Positive serology for acetylcholine receptor (AChR) autoantibodies

- QMG score ≥ 12 at Screening and Randomization

- No change in corticosteroid dose for at least 30 days prior to Randomization or
anticipated to occur during the 12-week Treatment Period

- No change in immunosuppressive therapy, including dose, for at least 30 days prior to
Randomization or anticipated to occur during the 12-week Treatment Period

Exclusion Criteria:

- Thymectomy within 6 months prior to Randomization or scheduled to occur during the 12
week Treatment Period

- History of meningococcal disease

- Current or recent systemic infection within 2 weeks prior to Randomization or
infection requiring intravenous (IV) antibiotics within 4 weeks prior to Randomization